阿托伐他汀对高血压大鼠肾脏血管紧张素转换酶2表达的影响

中国临床药理学与治疗学 ›› 2008, Vol. 13 ›› Issue (11): 1243-1248.

阿托伐他汀对高血压大鼠肾脏血管紧张素转换酶2表达的影响

张林叶¹, 邢文², 王安才²

¹芜湖市第二人民医院心内科, 芜湖 241000, 安徽;
²皖南医学院弋矶山医院干内科, 芜湖 241001, 安徽

收稿日期:2008-07-14 修回日期:2008-11-03 出版日期:2008-11-26 发布日期:2020-10-14
通讯作者: 王安才,男, 博士, 教授, 主任医师, 硕士生导师, 研究方向:心血管病临床。Tel:0553-5739313 E-mail: yjswac@sina.com
作者简介:张林叶, 男, 硕士, 主治医师, 研究方向:高血压病防治与冠脉介入治疗。Tel:0553-3909510 E-mail: zhanglinye1791@163.com

Effects of atorvastatin on renal angiotensin-converting enzyme 2 expression in hypertensive rats

ZHANG Lin-ye¹, XING Wen², WANG An-cai²

¹Department of Cardiology, Wuhu NO.2 People’s Hospital, Wuhu 241000, Anhui, China;
²Department of Cardiology, Yijishan Hospital, Wannan Medical College, Wuhu 241001, Anhui, China

Received:2008-07-14 Revised:2008-11-03 Online:2008-11-26 Published:2020-10-14

摘要/Abstract

摘要： 目的: 观察阿托伐他汀对两肾一夹(2K1C)高血压大鼠肾脏血管紧张素转换酶2(ACE2) 表达的影响, 探讨阿托伐他汀降血压作用可能的新的作用机制。方法: 40 只雄性Wistar 大鼠随机分为5 组(每组8 只) :假手术组、高血压组、缬沙坦组(20 mg·kg^-1·d^-1) 、阿托伐他汀组(10 mg·kg^-1 ·d^-1) 和阿托伐他汀组(30 mg·kg^-1·d^-1) 。鼠尾容积法测定术前、术后1周及药物干预后4 、8 周的SBP 变化。8 周后, 免疫组化法检测肾脏ACE2 蛋白表达, 放射免疫分析法测定心肌组织血管紧张素Ⅱ(Ang Ⅱ) 水平,RT-PCR 法检测肾脏组织ACE2 mRNA 表达。结果: 高剂量阿托伐他汀组SBP 较高血压组降低显著(P<0.01) ;高剂量阿托伐他汀组较高血压组降低心肌组织Ang Ⅱ 浓度显著(P<0.01) ;RTPCR显示缬沙坦组和低、高剂量阿托伐他汀组肾脏组织ACE2 mRNA 的表达较高血压组不同程度增高(P<0.05) 。结论: 2K1C 高血压大鼠肾脏组织ACE2 蛋白、ACE2 mRNA 表达降低。阿托伐他汀在降低高血压大鼠SBP 的同时, 降低心肌组织Ang Ⅱ浓度, 增加肾脏组织ACE2 蛋白、ACE2 mRNA表达。

关键词: 高血压, 血管紧张素转换酶2, 血管紧张素Ⅱ, 阿托伐他汀

Abstract: AIM: To observe the effects of atorvastatin on the expressions of renal angiotensin-converting enzyme 2 (ACE2) in two kidney and one-clip (2K1C) hypertensive rats and to explore new possible mechanism of atorvastatin in decreasing systolic blood pressure(SBP). METHODS: 40 male Wistar rats were randomly divided into five groups (8 in each group): sham operation group, 2K1C hypertension group, 2K1C +valsartan group(20 mg·kg^-1·d^-1), low dose atorvastatin group (10 mg·kg^-1 ·d^-1) and high dose atorvastatin group(30 mg·kg^-1 ·d^-1). SBP was measured by tail-cuff method before and one week after operation as well as 4 weeks and 8 weeks after drug intervention. After 8 weeks the renal ACE2 protein expression, myocardial Ang Ⅱ level and kidney ACE2 mRNA expression were determined by immunohistochemistry, radioimmunoassay and RT-PCR, respectively. RESULTS: The SBP and angiotensin Ⅱ concentration of rat myocardial tissue in high dose atorvastatin group were significantly decreased compared with those of the hypertension group (P<0.01). RT-PCR results showed that the levels of renal ACE2 mRNA expression in hypertension group was decreased to a certain extent compared with those of the Valsartan group, low and high doses of atorvastatin groups (P<0.05). CONCLUSION: Kidney ACE2 protein and ACE2 mRNA expression are deceased in 2K1C hypertensive rats. The SBP and the concentration of angiotensin Ⅱin rat cardiac tissue are decreased and the expressions of ACE2 and ACE2mRNA in renal tissue are increased in atorvastatin groups.

Key words: hypertension, angiotensin-converting enzyme 2, angiotensin Ⅱ, atorvastatin

中图分类号:

R965.2

张林叶, 邢文, 王安才. 阿托伐他汀对高血压大鼠肾脏血管紧张素转换酶2表达的影响[J]. 中国临床药理学与治疗学, 2008, 13(11): 1243-1248.

ZHANG Lin-ye, XING Wen, WANG An-cai. Effects of atorvastatin on renal angiotensin-converting enzyme 2 expression in hypertensive rats[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(11): 1243-1248.

参考文献

[1] Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin- convertingenzym-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9[J]. Circ Res, 2000, 87(5): E1-E9.
[2] Hamming I, Timens W, BulthuisML, et al. Tisstle dlstribution of ACE2 protein, the functional receptor for SARS coronavirus.A first step in understanding SARS pathogenesis[J]. J Pathol, 2004, 203(2): 631-637.
[3] Wei CC, Meng QC, Palmer R, et al. Evidence for angiotensin- converting enzyme and chymase mediated angiotensin Ⅱ formation in the intersitial fluid space of the dog heart in vivo[J]. Circulation, 1999, 99(19): 2583-2589.
[4] Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzymerelated carboxypeptidase[J]. J Biol Chem, 2002, 277(17): 14838-14843.
[5] Iwata M, Cowling RT, Gurantz D, et al. Angiotensin (1 -7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects[J]. Am J Physiol Heart Circ Physiol, 2005, 289(6): H2356-2363.
[6] Grobe JL, Mecca AP, Lingis M, et al. Prevention of angiotensin II-induced cardiac remodeling by angiotensin (1 -7)[J]. Am J Physiol Heart Circ Physiol, 2007, 292(2): H736-742.
[7] Fan X, Wang Y, Sun K, et al. Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women[J]. Clin Pharmacol Ther, 2007, 82(2): 187-196.
[8] Crackower MA, Sarao R, Oudit GY, Angiotensin-converting enzyme 2 is an essential regulator of heart function[J]. Nature, 2002, 417(6891): 822-828.
[9] Laufs U, La Fata V, Plutzky J, et al. Upregulatlon of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors[J]. Circulation, 1998, 97(12): l129-1135.
[10] Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis innormocholesterolemic animals[J]. NatMed, 2000, 6(9): 1004-1010.
[11] Rikitake Y, Kawashima S, Takeshita S, et al. Antioxidative properties of fluvastatin an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits[J]. Atherosclerosis, 2001, 154(1): 87-96.
[12] Hemandez-Perem O, Perez-Sala D, Navam-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatinand simvastatln, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothehal cells[J]. J Clin Invest, 1998, 101(12): 2711-2719.
[13] Wassmann S, Laufs U, Baumer AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species[J]. Hypertension, 2001, 137(6): 1450-1457.
[14] Ichi T, Takeda K, Tokunou T, et al. Downregulation of angloteusin II type l receptorby hydrophobic 3-hydroxy-3- methy lghtaryl coenzyme A reductase inhibitors in vascular smooth muscle cells[J]. Arteriosder Thromb Vase Bil, 200l, 21(12): 1895-1901.
[15] Delbosc S, Cristol JP, Descomps B, et al. Simvastatin attemaltea cardiovaseularefects and oxidative stress inducde by angiotensin Ⅱ[J]. Arch Mal Coeur Vaiss, 2001, 94(11): 1199-1202.
[16] 吴逸南, 葛志明, 姜虹, 等. 血管紧张素转换酶2在自发性高血压大鼠肾脏表达与血压的关系研究[J]. 中国病理生理杂志, 2006, 22(4): 818-820.
[17] 王安才, 曹蘅, 汪俊元, 等. 阿托伐他汀对自发性高血压大鼠去外膜颈动脉内膜增生的影响[J]. 中国动脉硬化杂志, 2006, 14(10): 862-866.